Vaccine Adjuvant Market Size Worth USD 1.75 Billion in 2032 | Emergen Research
Emergen Research
7 min read
Emergen Research
Rising prevalence of infectious diseases and collaborations and partnerships among market players for adjuvant vaccine development and increasing focus on immunization programs are key factors driving market revenue growth
Vancouver, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The global vaccine adjuvant market size was USD 0.90 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.0% during the forecast period. Rising prevalence of infectious diseases and collaborations and partnerships among market players for adjuvant vaccine development and increasing focus on immunization programs are key factors driving market revenue growth
In addition, increasing collaborations and partnerships among market players for adjuvant vaccine development is another key factor driving revenue growth of the market. Collaborations and partnerships among market players for adjuvant vaccine development will enable pharmaceutical companies, research institutions, and governments to combine their resources and expertise. By working together, they can accelerate the Research & Development (R&D) of adjuvant vaccines, which will not only streamline the vaccine development process but also results in more cost-effective production, making adjuvant vaccines more affordable and accessible.
However, side effects and toxicity of adjuvants is a key factor, which could restrain market revenue growth. Aluminum adjuvants, although commonly used, can cause local injection site reactions, including pain and inflammation, and increase the risk of allergic responses. These adverse effects, particularly in pediatric vaccines, lead to concerns and reduced community acceptance. Adjuvants need to enhance immune responses without causing undue side effects to gain broader adoption, which highlights the challenge of developing adjuvants that strike a balance between effectiveness and safety.
A recent trend in the vaccine adjuvant market is increasing availability of synthetic adjuvants. Synthetic vaccine adjuvant development focus on overcoming limitations of existing adjuvants such as alum. Advancements in medicinal chemistry have enabled the design of synthetic adjuvants with defined structures and enhanced immunogenicity. Researchers are exploring novel compounds, including synthetic saponin analogues, α-GalCer derivatives, and other chemically modified molecules. These synthetic adjuvants aim to induce robust and tailored immune responses, addressing the limitations of traditional adjuvants.
Segment Insights
Application Insights:
On the basis of application, the global vaccine adjuvants market is segmented into research, commercial, and others. The research segment accounted for largest revenue share in the global vaccine adjuvants market in 2022 due to the critical role of research in advancing vaccine technology. In-depth research is essential to ensure their effectiveness and safety with genetic engineering enabling the development of vaccines for a broader range of diseases and creation of novel adjuvants. Research provides cost-efficacy data and long-term outcomes, addressing the demands of managed care organizations for evidence-based medicine.
Type Insights:
On the basis of type, the global vaccine adjuvants market is segmented into human and veterinary vaccine adjuvants. The veterinary vaccine adjuvants is expected to account for largest revenue share in the global vaccine adjuvants market over the forecast period due to increasing prevalence of infectious zoonotic diseases. Zoonotic diseases, which can be transmitted between animals and humans, are on the rise, which presents a dual threat to both animal and human populations.
The North America market accounted for largest revenue share in the global vaccine adjuvants market due to increasing number of government initiatives recommending and promoting vaccination in North America. Initiatives addressing diseases, such as tuberculosis, malaria, and Human Papillomavirus (HPV), is in turn, rising demand for vaccines and, consequently, vaccine adjuvants.
The Europe market is expected to register fastest revenue growth rate in the global vaccine adjuvants market during the forecast period due to technological advancements development of more effective and safer adjuvants. For instance, in June 2023, Zoetis launched CircoMax in Europe, a new vaccine designed to combat Porcine Circovirus type 2 (PCV2). Unlike earlier vaccines, CircoMax offers dual-genotype coverage (PCV2a and PCV2b), providing more extensive protection against the evolving PCV2d. This vaccine stimulates both cell-mediated and antibody-based immunity, closely mimicking a natural infection response.
Scope of Research
Report Details
Outcome
Market Size in 2022
USD 0.90 Billion
CAGR (2023–2032)
7.0%
Revenue Forecast To 2032
USD 1.75 Billion
Base Year For Estimation
2022
Historical Data
2019-2021
Forecast Period
2023–2032
Quantitative Units
Revenue in USD Billion and CAGR in % from 2023 to 2032
Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
Product, route of administration, usage, disease, application, type, and region
Regional Scope
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Country Scope
U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa
The global vaccine adjuvant market is moderately fragmented, with many large and medium-sized players accounting for majority of market revenue. Major businesses are using a variety of tactics, making mergers and acquisitions, strategic agreements, and contracts, as well as creating, experimenting with, and introducing more efficient vaccine adjuvant solutions in the market. Some major players included in the global vaccine adjuvant market report are:
Adjuvatis
GlaxoSmithKline PLC
Croda International PLC
Merck KGaA
TjKaiwei
OZ Biosciences
Brenntag Biosector
MVP Laboratories
Zhuoyue
Aphios
Novavax Inc.
MVP Technologies
Avanti Polar Lipids, Inc.
Invivogen
SEPPIC, Inc.
Spectrum Pharmaceuticals, Inc.
Agenus, Inc.
Brenntag Biosector A/S
CSL Corporate
GSK plc
Vaxart
Strategic Development
On May 23, 2023, Croda Pharma partnered with Botanical Solution Inc. (BSI) to accelerate the production of vaccine adjuvant QS-21, a vital component in adjuvant systems used in various vaccines, including those for RSV, malaria, and shingles. QS-21 is also employed in new vaccines and immunotherapy treatments, such as cancer. The collaboration aims to produce QS-21 sustainably from quillaja Saponaria plant cell culture, offering an eco-friendly alternative to harvesting mature trees. This partnership helps to address the limited sources of QS-21, allowing for production of next-generation adjuvant systems for new vaccine development. The move aligns with Croda's strategy to empower biologics delivery.
On January 17, 2023, Elicio Therapeutics developed lymph node-targeted adjuvants and vaccines for various aggressive cancers and infectious diseases. The company has entered into a definitive merger agreement with Angion Biomedica Corp to focus on advancing Elicio's proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a particular emphasis on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
For the purpose of this report, Emergen Research has segmented the global vaccine adjuvant market on the basis of type, application, deployment, enterprise size, component, vertical, and region:
Product Outlook (Revenue, USD Billion; 2019-2032)
Mineral Salt-based Adjuvant
Tensoactive Adjuvants
Adjuvant Emulsions
Liposome Adjuvants
Carbohydrate Adjuvants
Bacteria-derived Adjuvants
Virus-like Particles (VLP)
Other Product Types
Route of Administration Outlook (Revenue, USD Billion; 2019-2032)
Product Intramuscular
Subcutaneous
Oral
Intradermal
Intranasal
Usage Outlook (Revenue, USD Billion; 2019-2032)
Active Immunostimulants
Carriers
Vehicle Adjuvants
Disease Outlook (Revenue, USD Billion; 2019-2032)
Esophagus Infectious Diseases
Cancer
Others
Application Outlook (Revenue, USD Billion; 2019-2032)
Research Application
Commercial Application
Type Outlook (Revenue, USD Billion; 2019-2032)
Human Vaccine Adjuvants
Veterinary Vaccine Adjuvants
Regional Outlook (Revenue, USD Billion; 2019–2032)
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
